Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived NK Cell Infusion in High-risk AML and MDS
NCT02477787Phase 2Terminated
- Sponsor
- Asan Medical Center
- Start
- Jun 2015
- Primary completion
- Jun 2019
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of gegleucel in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Asan Medical Center. Started Jun 2015; status: terminated.
02
Drugs
gegleucel
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02477787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477787.